NRx Pharmaceuticals welcomes the newly-signed Executive Order

NRx Pharmaceuticals (NRXP) welcomes the newly-signed Executive Order: Accelerating Medical Treatments for Serious Mental Illness, signed by President Trump on April 18, 2026. In the Order, the President notes that, “It is the policy of my Administration to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that could save lives and reverse the crisis of serious mental illness in America.” “We thank President Trump, Secretary Kennedy, and Commissioner Makary for their leadership and decisive action to address America’s mental health crisis, particularly the devastating toll of PTSD and suicide among our veterans,” said Jonathan C. Javitt, MD, MPH, Chairman and CEO of NRx Pharmaceuticals. “The Administration has lent Presidential authority to a commitment to act with urgency on behalf of patients and families who can no longer wait. NRx shares that mission and is proud to be aligned with this Administration in advancing solutions for severe depression, PTSD, and the mental health of military personnel, veterans, and first responders.”